MediWound Ltd.
MDWD
NSD
Sector: Healthcare
Industry: Biotechnology
1.95
USD
0.05
(2.63%)
Optionable: Yes Market Cap: 59 M 90-day average vol: 97,538
Previous close: 1.9 Open: 1.9 Bid: 2.03 Ask: 2.03
52 week range
1.21 4.01
Last updated: Friday 12th August 2022
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started todaySearch for a stock
Are you?
Metrics
Valuation
Price per Sales TTM ($) | 3.61 |
Price per Book TTM ($) | 30.67 |
PE Ratio (TTM) | -3.50 |
Book Value per Share ($) | 0.06 |
5 Year PE Range-18.9 |
Returns
7 Day Return | 12.07% | |
1 Month Return | 11.43% | |
3 Month Return | 3.72% | |
1 Year Return | -44.76% | |
3 Year Return | -40.46% | |
5 Year Return | -70.00% | |
YTD Return | -17.37% |
Risk
Custom Beta One Year | 0.40 |
Custom Beta Three Years | 0.69 |
Beneish M Score | -3.40 |
Altman Z Score | -10.00 |
Analyst Estimates
Financial Health
Technicals
RSI (14 Day) | 64.05 |
14 Day SMA ($) | 1.73 |
14 Day EMA ($) | 1.78 |
Money Flow Index | 52.56 |
Average True Range | 0.13 |
50 Day SMA ($) | 1.73 |
200 Day SMA ($) | 2.22 |
ADX | 9.00 |
MACD | 0.03 |
Growth
Free Cash Flow QoQ Growth | 79.71% |
Free Cash Flow YoY Growth | 0.00% |
Revenue YoY Growth | 0.00% |
EPS QoQ Growth | -20.00% |
Revenue QoQ Growth | -19.68% |
EPS YoY Growth | 0.00% |
Profitability
Return on Assets TTM (%) | -50.98 |
Profit Margin TTM (%) | -62.6 |
Return on Equity TTM (%) | -422.69 |
Return on Capital TTM (%) | -294.57 |
Interest Coverage Ratio | -51.00 |
Gross Margin TTM (%) | 35.0 |
Chart
News
MediWound Announces Pricing of Public Offering of Ordinary Shares
Yahoo Finance 3/3/2022
MediWound slides on proposed stock offering
Seeking Alpha 3/2/2022
MediWound Ltd. Announces Proposed Public Offering of Ordinary Shares
Yahoo Finance 3/2/2022
MediWound to Present at Upcoming Investor Conferences in March
Yahoo Finance 3/1/2022
Earnings Preview: MediWound (MDWD) Q4 Earnings Expected to Decline
Yahoo Finance 2/17/2022
MediWound Awarded a U.S. Department of Defense Research Grant for the Development of NexoBrid for the U.S. Army
Yahoo Finance 2/17/2022
MediWound to Present at Upcoming Investor Conferences in February
Yahoo Finance 2/14/2022
MediWound Receives Additional $9M From BARDA For NexoBrid FDA Application Resubmission
Yahoo Finance 2/10/2022
MediWound wins $9M additional BARDA funding for NexoBrid
Seeking Alpha 2/10/2022
MediWound Announces Additional $9 Million in Funding from BARDA to Support NexoBrid BLA Resubmission and the Expanded Access Treatment Protocol
Yahoo Finance 2/10/2022
MediWound's EscharEx Mid-Stage Trial Meets Primary Goal In Venous Leg Ulcers
Yahoo Finance 1/24/2022
MediWound reports positive results from Phase 2 trial of EscharEx for debridement of chronic wounds
Seeking Alpha 1/24/2022
MediWound Announces Positive Topline Results From Its U.S. Phase 2 Trial of EscharEx for Debridement of Chronic Wounds
Yahoo Finance 1/24/2022
Investors one-year losses grow to 51% as the stock sheds US$9.8m this past week
Yahoo Finance 1/20/2022
MediWound reports positive initial data from Phase 2 EscharEx study in chronic, hard to heal wounds
Seeking Alpha 12/20/2021
MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of EscharEx Showing Effective and Rapid Debridement in Chronic and Hard to Heal Wounds
Yahoo Finance 12/20/2021
MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
Yahoo Finance 12/6/2021
Trend Analysis & Forecast
Read more on this trend analysis & forecast here - uptrenddowntrend.com
Trendlast: -3.014
Financials
MDWD Income Statement
Annual
| Dec-12 | Dec-13 | Dec-14 | Dec-15 | Dec-16 | Dec-17 | Dec-18 | Dec-19 | Dec-20 | Dec-21 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | 259000 | 601000 | 2 M | 2 M | 3 M | 32 M | 22 M | 24 M |
| Cost of sales | -267000 | -336000 | 2 M | 2 M | 1 M | 500000 | 977000 | 11 M | 13 M | 13 M |
| Gross operating profit | 0 | 0 | -2 M | -1 M | -77000 | 1 M | 2 M | 20 M | 8 M | 10 M |
| Selling Gen & administrative expense | 1 M | 4 M | 14 M | 13 M | 12 M | 9 M | 9 M | 10 M | 9 M | 9 M |
| Research & development expense | 2 M | 4 M | 5 M | 6 M | 7 M | 5 M | 4 M | 5 M | 8 M | 10 M |
| Operating income | -3 M | -8 M | -21 M | -21 M | -20 M | -14 M | -11 M | 4 M | -9 M | -11 M |
| floaterest income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| floaterest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other income net | 15 M | -864000 | 4 M | -614000 | 131000 | 57000 | 7 M | 122000 | -31000 | -1 M |
| Pre-tax Income (EBT) | 12 M | -9 M | -19 M | -22 M | -19 M | -15 M | -6 M | 2 M | -9 M | -14 M |
| Income taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 27000 |
| Net income from total operations | 11 M | -15 M | -19 M | -22 M | -19 M | -22 M | -1 M | 5 M | -9 M | -14 M |
| Minority floaterest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total net income | 11 M | -15 M | -19 M | -22 M | -19 M | -22 M | -1 M | 5 M | -9 M | -14 M |
| Preferred dividends | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net income available for common | 12 M | -9 M | -19 M | -22 M | -19 M | -15 M | -6 M | 2 M | -9 M | -14 M |
| Depreciation | 267000 | 336000 | 492000 | 503000 | 589000 | 567000 | 577000 | 1 M | 1 M | 1 M |
| Amortization | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income before depreciation (EBITDA) | 13 M | -6 M | -18 M | -20 M | -17 M | -13 M | -4 M | 6 M | -7 M | -11 M |
| Total Income available for floaterest expense (EBIT) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Basic EPS total | 0.54 | -0.75 | -0.95 | -1.02 | -0.86 | -0.95 | -0.04 | 0.18 | -0.34 | -0.5 |
| Diluted EPS total | 0.54 | -0.75 | -0.95 | -1.02 | -0.86 | -0.95 | -0.04 | 0.18 | -0.34 | -0.5 |
Top MarketXLS Rank stocks
Call: 1-877-778-8358
I am so happy you are here. My name is Ankur and I am the founder/CEO of MarketXLS. Over the past four years, I have helped more than 2500 customers to implement their own investment research strategies and monitoring systems in Excel.
Get Access to 1 Billion Usable Market data points IN YOUR EXCEL SHEETS WITH EASY TO USE EXCEL FUNCTIONS
Get started today
Stand with Ukraine
As the situation in Ukraine escalates, many of us in MarketXLS are left with emotions too overwhelming to name. If you’d like to show your support, but aren’t sure how to, we want to help make it easier for you to act.
For any amount donated, we’ll extend your MarketXLS subscription for double of the donated amount. Please send proof of your payment to support@marketxls.com to avail the extention
From all of us at MarketXLS, thank you!